Aeglea

[Not Yet Scheduled]
Aeglea is a clinical-stage biotechnology company that engineers next generation human enzymes with enhanced properties and novel activity to provide solutions for diseases with unmet medical need. Our lead molecule pegzilarginase, for the treatment of patients with the rare genetic disease Arginase 1 Deficiency, is currently enrolling in a global, pivotal Phase 3 trial in the US and Europe. In building on our metabolic franchise, we intend to file an IND or CTA for our second program for the treatment of Homocystinuria in the first quarter of 2020. Additionally, we are continuing IND-enabling activities for our Cystinuria program, where we intend to enter the clinic in 2020.
Ticker:
AGLE
Exchange:
NASDAQ
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Texas
Company HQ Country:
United States
Year Founded:
2013
Main Therapeutic Focus:
Lead Product in Development:
Pegzilarginase for Arginase 1 Deficiency
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
Chief Executive Officer
Aeglea BioTherapeutics